Amgen

Is Amgen’s Outcomes-Based Pricing Model for Repatha Benefiting Patients and Payers?
Is Amgen’s Outcomes-Based Pricing Model for Repatha Benefiting Patients and Payers?
Xtalks
Amgen
Repatha
outcome-based pricing
drug pricing
patients
Flag link:
Amgen's money-back offer on Repatha isn't all that meaningful, researchers find
Amgen's money-back offer on Repatha isn't all that meaningful, researchers find
Biopharma Dive
Amgen
Repatha
Flag link:
Amgen darkens the mood in new Repatha TV ads, warning of heart and stroke risks
Amgen darkens the mood in new Repatha TV ads, warning of heart and stroke risks
Fierce Pharma
Amgen
Repatha
DTC ads
heart attack
stroke
Flag link:
Will Blincyto's Expanded FDA Approval Open the Door for Wider Use of MRD as a Biomarker or Endpoint?
Will Blincyto's Expanded FDA Approval Open the Door for Wider Use of MRD as a Biomarker or Endpoint?
RAPS.org
Amgen
Blincyto
ALL
B-cell precursor ALL
Flag link:
Novartis Likely Delayed In Launching Copycat Of Amgen Blockbuster
Novartis Likely Delayed In Launching Copycat Of Amgen Blockbuster
Investors Business Daily
Novartis
Amgen
Enbrel
biosimilars
Flag link:
Investors in AbbVie, Lilly, Amgen and more set to vote on executive pay, drug pricing
Investors in AbbVie, Lilly, Amgen and more set to vote on executive pay, drug pricing
Fierce Pharma
AbbVie
Eli Lilly
Amgen
executive pay
drug pricing
Flag link:
Amgen and Allergan Hopeful that Herceptin Biosimilar Approval Will Be Around the Corner
Amgen and Allergan Hopeful that Herceptin Biosimilar Approval Will Be Around the Corner
Xtalks
Amgen
Allergan
Herceptin
biosimilars
ABP 980
CHMP
EMA
Roche
Flag link:
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
Endpoints
drug launches
Hemlibra
Roche
Biktarvy
Gilead Sciences
Ozempic
Novo Nordisk
Erleada
JNJ
Shingrix
GSK
Patisiran
Alnylam
Sanofi
Epidiolex
GW Pharma
Aimovig
Amgen
Novartis
lanadelumab
Shire
Elagolix
AbbVie
Steglatro
Pfizer
Merck
Sublocade
Indivior
Flag link:
Why Amgen Shouldn't Use Its War Chest For A Celgene Megamerger
Why Amgen Shouldn't Use Its War Chest For A Celgene Megamerger
Investors Business Daily
Amgen
Celgene
M&A
Alexion
AstraZeneca
Flag link:
Drug companies are beginning to wake up to this new risk factor
Drug companies are beginning to wake up to this new risk factor
Marketwatch
pharma industry
co-pay coupons
Pfizer
Sanofi
Amgen
Novartis
Flag link:
Amgen faces tough one-two blow as competition mounts for Repatha and Sensipar
Amgen faces tough one-two blow as competition mounts for Repatha and Sensipar
Fierce Pharma
Amgen
Repatha
Sensipar
generics
Sanofi
Regeneron
Praluent
Flag link:
Top 5 boards for week ending March 10, 2018
Top 5 boards for week ending March 10, 2018
CP Wire
Daiichi Sankyo
Shire
Amgen
Sanofi
AstraZeneca
Flag link:
FDA Approves First Generic Versions of Amgen’s Sensipar
FDA Approves First Generic Versions of Amgen’s Sensipar
RAPS.org
FDA
generics
Amgen
Sensipar
Cipla
Aurobindo
Flag link:
Top 5 viewed boards for week ending March 3, 2018
Top 5 viewed boards for week ending March 3, 2018
CP Wire
cafepharma
Daiichi Sankyo
Shire
Allergan
Amgen
Sanofi
sales meeting
layoffs
Esmya
Pfizer
Celgene
M&A
Flag link:
Top drugmakers are counting on two hot drug fields—migraine and NASH—but payers are ready to rumble
Top drugmakers are counting on two hot drug fields—migraine and NASH—but payers are ready to rumble
Fierce Pharma
migraines
NASH
Amgen
Eli Lilly
Teva Pharmaceutical
Allergan
Gilead Sciences
Novo Nordisk
Intercept Pharma
PBMs
Flag link:
The Moment Of Truth Is Coming For Struggling And Expensive Cholesterol Drugs
The Moment Of Truth Is Coming For Struggling And Expensive Cholesterol Drugs
Forbes
cholesterol
PCSK9 inhibitors
Sanofi
Regeneron
Praluent
Amgen
Repatha
Flag link:
3 Tough Questions for Amgen
3 Tough Questions for Amgen
Motley Fool
Amgen
payers
cash
margins
Flag link:
Amgen still far from performing an important acquisition
Amgen still far from performing an important acquisition
GoinPharma
Amgen
M&A
Flag link:
Amgen Q4 Earnings Results: 2 Things to Hate and 2 Things to Like
Amgen Q4 Earnings Results: 2 Things to Hate and 2 Things to Like
Motley Fool
Amgen
earnings
Flag link:
Amgen reports profit below analyst views, but beats expectations on earnings outlook
Amgen reports profit below analyst views, but beats expectations on earnings outlook
CNBC
Amgen
earnings
Flag link:

Pages